Key Points
- Director Robert Jr. Baltera bought 20,000 shares of Palisade Bio at $1.99 per share, increasing his direct ownership to 436,904 shares. The filing shows this was a 4.8% boost in his stake.
- Baltera has been actively accumulating shares over several recent trading days, including purchases of 25,000, 30,000, 20,000, 10,000, and 20,000 shares at prices around $1.96 to $2.05.
- Palisade Bio shares were down slightly to $1.96, while analysts currently hold a consensus Buy rating with an average price target of $8.83. The company recently reported a quarterly loss that missed estimates by $0.01 per share.
Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Jr. Baltera acquired 20,000 shares of the stock in a transaction dated Wednesday, July 8th. The stock was purchased at an average cost of $1.99 per share, with a total value of $39,800.00. Following the purchase, the director directly owned 436,904 shares of the company's stock, valued at $869,438.96. This trade represents a 4.80% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Robert Jr. Baltera also recently made the following trade(s):
- On Thursday, July 9th, Robert Jr. Baltera acquired 25,000 shares of Palisade Bio stock. The stock was acquired at an average price of $1.96 per share, with a total value of $49,000.00.
- On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The shares were acquired at an average price of $2.03 per share, for a total transaction of $60,900.00.
- On Monday, July 6th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The shares were acquired at an average price of $2.05 per share, for a total transaction of $41,000.00.
- On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.98 per share, for a total transaction of $19,800.00.
- On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was acquired at an average price of $1.98 per share, with a total value of $39,600.00.
Palisade Bio Stock Down 0.5%
Shares of PALI stock traded down $0.01 during trading hours on Friday, hitting $1.96. 3,452,719 shares of the company's stock traded hands, compared to its average volume of 4,494,371. The stock's 50 day simple moving average is $1.92 and its 200 day simple moving average is $1.92. The stock has a market cap of $340.22 million, a PE ratio of -1.94 and a beta of 1.50. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.85.
Palisade Bio (NASDAQ:PALI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). As a group, equities research analysts expect that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
PALI has been the topic of several recent research reports. Weiss Ratings raised Palisade Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 29th. HC Wainwright reissued a "buy" rating and issued a $2.00 price target on shares of Palisade Bio in a research note on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded Palisade Bio to a "strong-buy" rating in a research report on Thursday, June 25th. Wolfe Research began coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an "outperform" rating and a $7.00 price objective on the stock. Finally, Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a report on Sunday, July 5th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.83.
View Our Latest Analysis on PALI
Hedge Funds Weigh In On Palisade Bio
Hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new position in Palisade Bio in the fourth quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new stake in Palisade Bio during the 4th quarter worth about $28,000. Atom Investors LP bought a new position in shares of Palisade Bio in the 4th quarter worth about $33,000. Finally, Barclays PLC bought a new position in shares of Palisade Bio in the 4th quarter worth about $35,000. Institutional investors own 11.79% of the company's stock.
Palisade Bio Company Profile
(
Get Free Report)
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
